<DOC>
	<DOCNO>NCT02143050</DOCNO>
	<brief_summary>The main purpose evaluate clinical response , safety survival FDA approve drug Dabrafenib , Trametinib combination Metformin . Investigators hypothesize combination FDA approve non toxic dose oral Metformin B-Raf inhibitor , Dabrafenib MEK inhibitor , Trametinib yield little toxicity improve clinical outcome term objective response rate survival metastatic melanoma patient .</brief_summary>
	<brief_title>Study Dabrafenib , Trametinib Metformin Melanoma Patients</brief_title>
	<detailed_description>The study single-arm , single center , uncontrolled phase I/II trial estimate safety combine treatment estimate efficacy term objective response rate patient stage IIIC Stage IV melanoma treat dabrafenib/trametinib metformin .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Dabrafenib</mesh_term>
	<criteria>Male female patient &gt; 18 year age Patients histologically confirm BRAFV600E melanoma ( Stage IIIC Stage IV , American Joint Commission Cancer ) Eastern Cooperative Oncology Group Performance Status 0 2 Life expectancy &gt; 3 month At least 1 site radiographically measurable disease RECIST 1.1 Adequate hematologic , renal , liver function define laboratory value perform within 42 day prior initiation dosing : Absolute neutrophil count &gt; 1.0 x 10⁹/L Platelet count &gt; 50 x 10⁹/L Hemoglobin &gt; 8 g/dL Serum creatinine &lt; 2 x upper limit normal Total serum bilirubin &lt; 3 x ULN Serum aspartate transaminase serum alanine transaminase &lt; 3 x ULN , &lt; 4 x ULN liver metastases present Fertile male use effective method contraception treatment least 3 month completion treatment , direct physician Premenopausal female females &lt; 2 year onset menopause negative pregnancy test Screening . Premenopausal females must agree use acceptable method birth control time negative pregnancy test 90 day last dose study drug Females nonchildbearing potential may include either surgically sterile postmenopausal &gt; 1 year Before study entry , write informed consent must obtain patient prior perform study related procedure Prior treatment Vemurafenib Dabrafenib Known hypersensitivity Metformin component Received radiotherapy non CNS disease within 2 week prior commence study treatment recover side effect radiation relate toxicity Grade &lt; 1 , except alopecia Pregnant , breast feeding , refuse double barrier contraception , oral contraceptive , avoidance pregnancy measure Have uncontrolled infection medical condition could interfere conduct study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Unresectable melanoma Stage IIIC Stage IV BRAF V600E+</keyword>
</DOC>